| You are here: Home: BCU 1|2002: Daniel R Budman, MD: Select publications
SELECT REFERENCES
CAPECITABINE
Abushullaih S et al. Characterizing hand-foot syndrome (HFS) caused by capecitabine. Proc ASCO 2000;Abstract 2403.
Blum JL et al. Multicenter phase II study of capecitabine in paclitaxelrefractory metastatic breast cancer. J Clin Oncol 1999;17:485-93. Abstract
Blum JL. Xeloda in the treatment of metastatic breast cancer. Oncology 1999;57 Suppl 1:16-20. Abstract
Budman DR. Capecitabine. Invest New Drugs 2000;18(4):355-63. Abstract
Budman DR et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: Capecitabine. J Clin Oncol 1998;16(5):1795-802. Abstract
Chin SF et al. Use of "bag balm" as topical treatment of palmar-plantar erythrodysesthesia syndrome (PPES) in patients receiving selected chemotherapeutic agents. Proc ASCO 2001;Abstract 1632.
Dooley M, Goa KL. Capecitabine. Drugs 1999;58(1):69-76; discussion 77-8. Abstract
Gradishar WJ. Clinical status of capecitabine in the treatment of breast cancer. Oncology (Huntingt) 2001;15(1 Suppl 2):69-71; discussion 72. Abstract
Kuhn JG. Fluorouracil and the new oral fluorinated pyrimidines. Ann Pharmacother 2001;35(2):217-27.Abstract
Lauman MK, Mortimer J. Effect of pyridoxine on the incidence of palmar plantar erythroderma (PPE) in patients receiving capecitabine. Proc ASCO 2001;Abstract 1565.
Michaud LB et al. Improved therapeutic index with lower-dose capecitabine in metastatic breast cancer (MBC) patients (Pts). Proc ASCO 2000; Abstract 402.
O'Shaughnessy et al. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda (capecitabine). Proc ASCO 2000;Abstract 400.
Reigner B et al. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001;40(2):85-104. Abstract
Schilsky RL. Pharmacology and clinical status of capecitabine. Oncology (Huntingt) 2000 Sep;14(9):1297-306; discussion 1309-11. Abstract
Verweij J. Rational design of new tumor activated cytotoxic agents. Oncology 1999;57 Suppl 1:9-15. Abstract
|
